AI assistant
Silo Pharma, Inc. — Director's Dealing 2024
Apr 8, 2024
35304_dirs_2024-04-08_511b960a-b21e-4793-a166-2987b476c78d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Silo Pharma, Inc. (SILO)
CIK: 0001514183
Period of Report: 2024-04-04
Reporting Person: Weisblum Eric (Director, CEO and President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-04-04 | Common Stock | P | 600 | $1.96 | Acquired | 175032 | Direct |
| 2024-04-05 | Common Stock | P | 400 | $2.03 | Acquired | 175432 | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.96 to $1.97. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.00 to $2.05. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.